Investigation Report on China Linezolid Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||332302|
|出版日期||內容資訊||英文 20 Pages
|Linezolid的中國市場 Investigation Report on China Linezolid Market, 2010-2019|
|出版日期: 2015年06月04日||內容資訊: 英文 20 Pages||
Linezolid，是由Pharmacia & Upjohn所開發的合成Oxazolidinone化合物。在2000年取得FDA認證的Linezolid之同年銷售量為1億5000萬美元，但從2013年到2014年期間卻達到了13億5000萬美元。近幾年中國市場中Linezolid的銷售量非常不穩定，2014年的銷售量為9300萬人民幣，低於2010年當時記錄的銷售量 (1億1300萬人民幣) 。
Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).
Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid's crystal form shall expire in 2021, its price stays high.
Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.
Generally speaking, linezolid enjoys a vast demand in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: